A groundbreaking study from the National Cancer Centre Singapore (NCCS), in close collaboration with Duke-NUS Medical School, has uncovered a critical mechanism by which tumors in head and neck squamous cell carcinoma (HNSCC) dodge the body's natural defenses. This discovery sheds light on why these aggressive cancers often spread early to lymph nodes, complicating treatment and worsening outcomes for patients. Conducted by a multidisciplinary team led by Professor Gopal Iyer, the research highlights the role of midkine (MDK), a protein secreted by pre-metastatic cancer cells that exhausts key immune fighters, CD8+ T cells. For Singapore's higher education institutions, this work exemplifies the cutting-edge research environment fostering the next generation of oncologists and immunologists.

Head and neck squamous cell carcinoma represents a significant challenge in Singapore, where cancer incidence continues to climb. With NCCS handling the majority of public sector cases, such insights are pivotal for advancing precision medicine. The study's findings, derived from analyzing tumors from 14 patients using advanced single-cell RNA sequencing, reveal how tumors manipulate immune responses right from the primary site, enabling metastasis before symptoms even appear.

🔬 Decoding Cancer Immune Evasion: From Basics to Breakthrough

The immune system acts as the body's vigilant guardian, constantly patrolling for threats like viruses or mutated cells. Cytotoxic CD8+ T cells, often called killer T cells, are frontline warriors that recognize and destroy abnormal cells by binding to specific surface markers. In cancer, however, tumors develop sophisticated evasion tactics. Immune evasion refers to strategies tumors employ to hide from or suppress these defenders, allowing unchecked growth and spread.

Common mechanisms include downregulating major histocompatibility complex (MHC) class I molecules, which display tumor antigens to T cells, or secreting immunosuppressive factors. In HNSCC, the NCCS-Duke-NUS team pinpointed a novel pathway involving MDK. This growth factor, typically involved in development, is hijacked by cancer cells to signal 'do not attack' to CD8+ T cells via their receptors, leading to T cell exhaustion—a state where cells become dysfunctional after prolonged stimulation without success.

Study Design: Single-Cell Insights into Tumor Dynamics

Leveraging state-of-the-art single-cell RNA sequencing (scRNA-seq), the researchers profiled over 100,000 cells from primary tumors and matched metastatic lymph nodes. This technique dissects individual cell gene expression, unveiling heterogeneity within tumors—mixtures of cell types with varying behaviors. They identified pre-metastatic clones in primary sites expressing high MDK, correlating with exhausted CD8+ T cells in nodes.

Mouse models engrafted with patient-derived xenografts (PDX) confirmed causality: MDK blockade reduced lymph node metastasis by rejuvenating T cells. Combining MDK inhibition with anti-programmed death-1 (PD-1) therapy, a checkpoint inhibitor, synergistically boosted anti-tumor activity, converting exhausted T cells into effective killers. These findings, published after rigorous validation, underscore Singapore's prowess in translational research.

Step-by-Step: The MDK-Mediated Evasion Pathway

1. Primary Tumor Initiation: HNSCC arises in mucosal linings of mouth, throat, or larynx, often from tobacco, alcohol, or HPV.
2. Pre-Metastatic Clone Emergence: Subpopulations upregulate MDK production.
3. MDK Secretion and Receptor Binding: MDK binds MDK receptors (e.g., ALK, LRP1) on CD8+ T cells infiltrating the tumor microenvironment (TME).
4. T Cell Exhaustion: Signaling induces exhaustion markers like PD-1, TIM-3, LAG-3, impairing cytotoxicity.
5. Immune Surveillance Failure: Exhausted T cells fail to eliminate pre-metastatic cells.
6. Early Dissemination: Cancer cells traffic to draining lymph nodes undetected.
7. Metastasis Establishment: Secondary tumors form, evading systemic immunity.

This sequence explains occult nodal metastases at diagnosis, seen in 40-50% of HNSCC cases, per regional data.

Singapore's Head and Neck Cancer Burden

Cancer remains Singapore's top killer, with over 20,000 new diagnoses annually projected for 2026, per National Cancer Registry trends. HNSCC accounts for about 4% of cases, roughly 800 annually, predominantly in men over 60. Incidence rises with aging population and lifestyle factors, despite declining tobacco use. NCCS reports improved survival via multidisciplinary care, but metastasis drops 5-year survival below 50%.Singapore Cancer Trends

Early detection via screening lags, emphasizing research like this for biomarkers.

Duke-NUS and Singapore's Research Ecosystem

Duke-NUS Medical School, Singapore's premier graduate medical institution, played a central role, training clinician-scientists in oncology. Affiliated with SingHealth, it integrates clinical care with lab research. Collaborators from NUS Yong Loo Lin School of Medicine and A*STAR's SIgN bolstered bioinformatics and immunology expertise. This ecosystem, funded by NMRC and A*STAR, positions Singapore as Asia's immuno-oncology hub, attracting global talent.

Such studies exemplify PhD programs at Duke-NUS in Cancer Biology, emphasizing single-cell tech and AI-driven analysis.

Therapeutic Horizons: From Bench to Bedside

MDK inhibition revives exhausted T cells, synergizing with PD-1 blockers like pembrolizumab, standard in metastatic HNSCC. Preclinical success suggests clinical trials, potentially reducing nodal relapse. Broader implications for other MDK-high cancers like bladder or prostate. Singapore's trials infrastructure at NCCS accelerates translation.Full Study in Nature Communications

Challenges include TME complexity; multi-omics integration, ongoing at Duke-NUS, promises personalized immunotherapy.

Careers in Singapore's Oncology Research

This breakthrough highlights vibrant opportunities for higher ed graduates. Duke-NUS offers PhD/postdoc positions in tumour immunology, with stipends ~SGD 3,500/month plus housing. NCCS recruits research fellows; NTU's Lee Kong Chian School of Medicine expands immuno-oncology labs. Skills in scRNA-seq, CRISPR, flow cytometry in demand. Singapore's Research, Innovation and Enterprise 2025 plan invests SGD 25B, creating 20,000 jobs.

International collaborations with Southampton enhance global exposure for trainees.

Stakeholder Perspectives and Challenges

Prof Iyer notes: "Cancer forces immune cells to work overtime, like burnt-out employees." Patients advocate integrated care; oncologists stress multimodal therapy. Challenges: resistance, trial access. Singapore addresses via National Precision Medicine program, genotyping 100,000 citizens.

Photo by Buddha Elemental 3D on Unsplash

Future Outlook: Transforming Cancer Care

By 2030, immunotherapy could double HNSCC survivors. Singapore aims for 'Warp Speed Cancer' via AI trials. For students, this signals booming field—pursue MSc/PhD at Duke-NUS for impact. Actionable: screen high-risk (smokers), support research funding.

This NCCS-led advance cements Singapore's leadership, blending academia and clinic for breakthroughs benefiting Asia-Pacific.